Skip to Main Content

Program

Angiogenesis, Exudation, and Degeneration 2020

Saturday, February 8, 2020
Program is subject to change

7:00 am Registration and Continental Breakfast
7:50 Welcome and Overview / Pre-Program Test
Philip J. Rosenfeld, MD, PhD, Harry W. Flynn, Jr., MD, and Thomas A. Albini, MD
  Session I: Aging, Disease Pathogenesis, and Imaging
Moderators: Philip J. Rosenfeld, MD, PhD and Zohar Yehoshua, MD, MHA
8:00 Metabolic Networks and the RPE-Photoreceptor Ecosystem in Aging and Degeneration
Philip Luthert, MBBS

8:08 Deep Learning and Reticular Pseudodrusen
Emily Y. Chew, MD
8:16 Ultrahigh Speed OCTA for Assessing Choricapillaris Flow Impairment
James G. Fujimoto, PhD
8:24 Challenges in Imaging the Choriocapillaris
Richard F. Spaide, MD
8:32 Choriocapillaris Quantification with Phansalkar's Local Thresholding: Do's and Don'ts
Zhongdi Chu, PhD

8:40 Imaging of Choriocapillaris Associated with Drusen in AMD
Philip J. Rosenfeld, MD, PhD

8:48 Choriocapillaris in Intermediate AMD
Robyn Guymer, MBBS, PhD, FRANZCO

8:56 Choriocapillaris in Myopia
SriniVas R. Sadda, MD

9:04 Choroidal Vessel Imaging and Quantification
Ruikang (Ricky) Wang, PhD

9:12 Structural OCT Imaging to Differentiate Between PIC, PIC-CNV and Myopic-CNV
Xiaoxin Li, MD

  Session II: Retinal Diseases and Functional Endpoints
Moderators: Thomas A. Albini, MD and Jorge A. Fortun, MD
9:20 Retina Trends – A VC’s Perspective
Emmett T. Cunningham, Jr., MD, PhD, MPH

9:28 MacTel2 as a “Serine/Ceramide-Opathy”
Martin Friedlander, MD, PhD

9:36 Epidemiology of Common Retinal Diseases in Retina Practices in the United States
Andrew A. Moshfeghi, MD, MBA

9:44 Functional Imaging of Mitochondria in Retinal Diseases
Rishi P. Singh, MD

9:52 Novel Analytics to Examine Impact of Fluctuations in Retinal Thickness on Visual Outcomes
Usha Chakravarthy, MD

10:00 Integrating Microperimetry into Clinical Trials of Nonexudative AMD
Nadia Waheed, MD

10:08 Rod-and-Cone-Mediated Vision in Eyes with Hyperreflective Foci: An Outcome Measure for Oil Spill Trials?
Christine A. Curcio, PhD

10:16 Normal and Low Luminance Quantitative Contrast Sensitivity: A Novel Functional Endpoint for Rapid Measurement of Spatial Contrast Sensitivity Functions in Dry AMD
Karl G. Csaky, MD, PhD

  Session III: AMD I
Moderators: Philip J. Rosenfeld, MD, PhD and Raquel Goldhardt, MD
10:24 Update on Gene Therapy for Complement Inhibition
Jay S. Duker, MD

10:32 Kamuvudines for AMD: The Saga Continues
Jayakrishna Ambati, MD

10:40 Phase 1 Results of a Systemic Antisense Inhibitor of Complement Factor B for Geographic Atrophy
Sunil S. Patel, MD, PhD

10:48 Phase 1 Single and Multiple Dose Safety Study of Anti-High Temperature Requirement A1 (HtrA1) in Geographic Atrophy (GA)
Vrinda Hershberger, MD, PhD

10:56 Update on Elamipretide for the Treatment of AMD
Scott W. Cousins, MD

11:04 Three-Part Talk on Anti-Integrin Therapy with Risuteganib in Dry AMD 1-Pre-Clinical Data
Glenn J. Jaffe, MD

  2-Phase 2 Study Results
Peter K. Kaiser, MD

  3-Structure/Function Correlations
Glenn J. Jaffe, MD

11:20 Update on Brimonidine Intravitreal Implant for Dry AMD
Ryan Rich, MD

11:28 Avacincaptad Pegol, a Novel C5 Inhibitor for the Treatment of Geographic Atrophy
Karl G. Csaky, MD, PhD

11:36 Pegcetacoplan, a Novel C3 Inhibitor for the Treatment of Geographic Atrophy
Cedric G. Francois, MD, PhD

  Session IV: AMD II
Moderators: Harry W. Flynn, Jr., MD and Luis J. Haddock, MD
11:44 PROCON Year 2 Results
Jeffrey S. Heier, MD

11:52 Non-Neovascular Exudative Age Related Macular Degeneration:
How to Unmask the Masquerader
David Sarraf, MD

12:00pm Update on Stem Cell Therapies for AMD
Amir H. Kashani, MD, PhD

12:08 Retinal Implants: Where Are We Now?
Jean-François Korobelnik, MD

12:16 Advanced Retinal Implants
Mark S. Humayun, MD, PhD

12:24 Lunch
  Session V: Macular Neovasculation in AMD
Moderators: Philip J. Rosenfeld, MD, PhD and Stephan Michels, MD, MBA
1:00 The Importance of MNV Type Classification in the Interpretation of the Results of Clinical Trials
Giovanni Staurenghi, MD

1:08 Detection of Non-Exudative Subclinical MNV in AMD from Structural OCT Scans Using Deep Learning
Aaron Y. Lee, MD

1:16 AI Based Fluid Quantification on Serial OCT Images from a Patient Self-operated Home OCT Device
Anat Loewenstein, MD

1:24 Automated Volumetric Assessment of Subclinical Non-Exudative MNV Using SS-OCTA
Luis de Sisternes, PhD

1:32 Rotational 3D OCTA
Giuseppe Querques, MD, PhD

  Session VI: Polypoidal Choroidal Vasculopathy
Moderators: Philip J. Rosenfeld, MD, PhD and Jackie Kovach, MD
1:40 Diagnosis of PCV Using SS-OCTA
Hiroko Terasaki, MD, PhD

1:48 Volume Rendering of OCTA in PCV
K. Bailey Freund, MD

1:56 A Comparison Study of Polypoidal Choroidal Vasculopathy Imaged with ICGA and SS-OCTA
Seung-Young Yu, MD

2:04 Longitudinal Changes in Subclinical PCV
Gemmy Cheung, MBBS, FRCOphth, FAMS, MCI

2:12 Longitudinal Observations of PCV Using SS-OCTA
Fenghua Wang, MD

  Session VII: Treatments for Neovasculation in AMD and ROP
Moderators: Thomas A. Albini, MD and Ninel Z. Gregori, MD
2:20 Immunology of Gene Therapy
Janet L. Davis, MD

2:28 Phase 1 study of Intravitreal Gene Therapy with DVM-022 for Neovascular AMD (OPTIC Trial)
David S. Boyer, MD

2:36 RGX-314 Gene Therapy for wAMD and Diabetic Retinopathy
Jeffrey S. Heier, MD

2:44 Treatment of Newly Diagnosed and Treatment Resistant Neovascular AMD with the Oral CCR3 Inhibitor ALK4290
Michael W. Stewart, MD

2:52 Results of the Phase I/II SUSHI Study of Intravitreal RBM-007 in Exudative AMD
Quan Dong Nguyen, MD, MSc

3:00 Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD
Diana V. Do, MD

3:08 Results of the Opthea OPT-302 Phase 2b Study: Combined VEGF-C / VEGF-D Suppression for nvAMD
Pravin U. Dugel, MD

3:16 Phase 2 LADDER Trial Using the Port Delivery System with Ranibizumab:
End of Study, Long-term Follow-up Results
Carl D. Regillo, MD

3:24 Faricimab Update
Karl G. Csaky, MD, PhD

3:32 Update on the Safety and Efficacy of Abicipar Pegol
Baruch D. Kuppermann, MD, PhD

3:40 Brolucizumab Update
Lawrence J. Singerman, MD

3:48 Do We Need More VEGF Blockade?- The Rationale for a Clinical Trial Testing High-Dose Aflibercept
David M. Brown, MD

3:56 Update on ROP and Anti-VEGF Clinical Trials
Darius M. Moshfeghi, MD

  Session VIII: Diabetes
Moderators: Harry W. Flynn, Jr. MD and Justin H. Townsend, MD
4:04 Effect of Industry Funding on Abstract Bias in the Literature for Intravitreal Pharmacotherapy for Retinal Vascular Disease
Jayanth Sridhar, MD

4:12 DRCR Retina Network Trials and Real World Experience
Jennifer Sun, MD

4:20 Diabetic Retinopathy Severity Score: Friend or Foe?
Lee M. Jampol, MD

4:28 AI-Assisted Approaches for Diabetic Retinopathy Screening
Michael S. Ip, MD

4:36 The Pattern and Density of Retinal Capillary Plexuses from the Fovea to the Periphery Using SS-OCTA
Ramin Tadayoni, MD, PhD

4:44 Wide-field SS-OCTA is Better than FA in Detecting Capillary Dropout, Neovascularization and IRMA in Diabetic Retinopathy
Toshinori Murata, MD, PhD

4:52 Wide-field SS-OCTA in Diabetic Retinopathy
Harry W. Flynn, Jr. MD

5:00 Development of DME in Fellow Eyes from VIVID/VISTA
Dilsher Dhoot, MD

5:08 Intravitreal Aflibercept for Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy (NPDR): 2-Year Outcomes of the Phase 3 PANORAMA Study
Charles C. Wykoff, MD, PhD

  Session IX: Diabetes, Uveitis, and Retinal Degenerations
Moderator: Philip J. Rosenfeld, MD, PhD and Thomas A. Albini, MD
5:16 Results of a Phase 1 Study Using the Integrin Antagonist THR-687 in Patients with DME
Arshad Khanani, MD

5:24 A Phase 2 Study of OCS-01: An Effective Topical Dexamethasone for DME
Pravin U. Dugel, MD

5:32 Front-line Local Therapies for Uveitis: From Clinical Trials to Practice
Steven Yeh, MD

5:40 Update on Therapeutic Superchoroidal Injection
Thomas A. Albini, MD

5:48 The Expanding Clinical Spectrum of S-Cone Enhanced Disease or NR2E3
Lawrence A. Yannuzzi, MD

5:56 Treatments and Clinical Trials in Inherited Retinal Degenerations
Byron L. Lam, MD

6:04 Results of a Clinical Trial Investigating N-acetylcysteine in Retinitis Pigmentosa
Peter A. Campochiaro, MD

6:12 Post-Program Test and Closing Remarks
6:20 Adjourn/Cocktail Reception